Research programme: breast cancer therapeutics - Bayer HealthCare Pharmaceuticals
Latest Information Update: 19 Feb 2009
Price : $50
At a glance
- Originator Berlex Biosciences
- Developer Bayer HealthCare Pharmaceuticals Inc.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 19 Feb 2009 Preclinical development is ongoing in USA
- 04 Apr 2007 Berlex is now called Bayer HealthCare Pharmaceuticals
- 19 Sep 2005 This programme is still in active development - BIO 2005: Annual International Convention (BIO 2005)